title: [Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].
abstract: OBJECTIVE
  To explore the clinical characteristics and prognosis of patients with primary testicular non-Hodgkin's lymphoma.
  
  
  METHODS
  The clinical profiles and prognostic factors of 21 cases newly diagnosed as primary testicular non-Hodgkin's lymphoma at Peking University Cancer Hospital from January 2005 to December 2012 were retrospectively analyzed.
  
  
  RESULTS
  Their median age was 59 (34-86) years. And they were classified as Ann Arbor stage I (n = 8), stage II (n = 2) and stage IV (n = 11). There were B symptoms (n = 4), extranodal involvement outside testis (n = 12) and elevated lactate dehydrogenase (LDH) at diagnosis (n = 6). The scores of international prognostic index (IPI) were 0-1 point (n = 10), 3 points (n = 10) and 4 points (n = 1). The regimens included orchidectomy as the initial treatment (n = 15), chemotherapy followed by radiotherapy (n = 7) and CNS prophylaxis during treatment (n = 15). All patients were pathologically diagnosed as diffuse large B-cell lymphoma. And 11 cases belonged to the non-germinal center B cell-like subgroup.First-line chemotherapy was either R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) or CHOP-like-based regimen. Complete response was achieved in 85.7% of patients. The median follow-up period was 18 (6-58) months. The 1, 2 and 3-year survival rates were 100%, 80% and 60% respectively. Statistical analysis showed that the first-line chemotherapy with rituximab was a prognostic factor (P = 0.038).Other factors included stage (P = 0.275), LDH level (P = 0.179) , β2-microglobulin level (P = 0.229) and IPI (P = 0.275) .
  
  
  CONCLUSIONS
  The prognosis of primary testicular non-Hodgkin's lymphoma is usually poor. The first-line chemotherapy with rituximab is a prognostic factor.
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.forename: Xiao-pei
authors.initials: XP
authors.lastname: Wang
authors.forename: Zhi-tao
authors.initials: ZT
authors.lastname: Ying
authors.forename: Wen
authors.initials: W
authors.lastname: Zheng
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
authors.forename: Ning-jing
authors.initials: NJ
authors.lastname: Lin
authors.forename: Ling-yan
authors.initials: LY
authors.lastname: Ping
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Deng
authors.forename: Yu-qin
authors.initials: YQ
authors.lastname: Song
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000175:diagnosis / Q000188:drug therapy*